Wechselwirkungen · Sunlenca
Sunlenca 300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 22–23
HOS-148338 · Präparat HOS-099874
22 Medicinal product by therapeutic Effects on concentrations. Recommendation concerning areas Mean percent change in AUC, co-administration with Sunlenca Cmax ANTIRETROVIRAL AGENTS Atazanavir/cobicistatb,d,e Lenacapavir: Co-administration is not (300 mg/150 mg once daily) AUC: ↑ 321% recommended (see section 4.4). Cmax: ↑ 560% Efavirenzb,d,f (600 mg once daily) Lenacapavir: AUC:↓ 56% Cmax:↓ 36% Etravirine Interaction not studied. Nevirapine Tipranavir/ritonavir Co-administration of etravirine, nevirapine, or tipranavir/ritonavir may decrease lenacapavir plasma concentrations, which may result in loss of therapeutic effect and development of resistance. Cobicistatb,d,g (150 mg once daily) Lenacapavir: No dose adjustment of lenacapavir AUC: ↑ 128% is required. Cmax:↑ 110% Darunavir/cobicistatb,d,h Lenacapavir: (800 mg/150 mg once daily) AUC:↑ 94% Cmax:↑ 130% Ritonavir Interaction not studied.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): atazanavir (HOS-086180) etravirine (HOS-088088) darunavir (HOS-086181) nevirapine (HOS-088064) ritonavir (HOS-084521) tipranavir (HOS-086184)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-02-26T15:19:00Z · SHA-256 5e82373c9638ee4d24450180684e7d233b6a19a1b3755e36a56d1822304f7bda · Passage 3f20579ced42d5294fbfb3d3bfff186cea6d35e1f5b9dc730ee9b96ec32e5a72 · Zeichen 4157–5815 im Abschnitt